KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Kala Pharmaceuticals(KALA) Newsfilter·2024-08-06 20:00
-- Closed 54.2 million as of June 30, 2024, together with anticipated funding remaining from CIRM award, expected to fund operations into 4Q 2025 – -- Topline data from Phase 2b CHASE trial of KPI-012 for PCED targeted in Q1 2025 -- ARLINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharm ...